Development of vaccines for prevention of Ebola virus infection.

Abstract

Ebola virus infection causes severe hemorrhagic fevers with high fatality rates up to 90% in humans, for which no effective treatment is currently available. The ongoing Ebola outbreak in West Africa that has caused over 14,000 human infections and over 5000 deaths underscores its serious threat to the public health. While licensed vaccines against Ebola virus infection are still not available, a number of vaccine approaches have been developed and shown to protect against lethal Ebola virus infection in animal models. This review aims to summarize the advancement of different strategies for Ebola vaccine development with a focus on the discussion of their protective efficacies and possible limitations. In addition, the development of animal models for efficacy evaluation of Ebola vaccines and the mechanism of immune protection against Ebola virus infection are also discussed.

• Authors: Ling Ye, Chinglai Yang
• Journal: Microbes and infection (Microbes Infect) Vol. 17 Issue 2 Pg. 98-108 (Feb 2015) ISSN: 1769-714X [Electronic] France
• PMID: 25526819 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
• Copyright: Copyright © 2015. Published by Elsevier Masson SAS.

Chemical References

• Ebola Vaccines

Topics

• Animals
• Communicable Disease Control
• Disease Models, Animal
• Ebola Vaccines (therapeutic use)
• Ebolavirus (immunology)
• Hemorrhagic Fever, Ebola (immunology, prevention & control)
• Humans